A prion is an infectious agent whose propagation depends on a self-templating change in protein structure rather than the replication of a conventional nucleic-acid genome. In mammalian prion diseases, an abnormal form of the host prion protein induces normally folded molecules of the same protein to adopt a disease-associated conformation. The resulting assemblies can accumulate, spread between tissues, and cause fatal degeneration of the nervous system. Unlike a virus, a prion has no demonstrated agent-specific DNA or RNA genome.
Prions cause scrapie in sheep and goats, bovine spongiform encephalopathy in cattle, chronic wasting disease in cervids, and several human disorders, including Creutzfeldt–Jakob disease. These conditions are collectively called transmissible spongiform encephalopathies. They are unusual because related disease processes can begin sporadically, arise from an inherited genetic variant, or follow exposure to infectious material. The term prion also has a broader use in experimental biology for self-propagating protein states, particularly in fungi, that need not cause disease.
The discovery of prions established that biological information can be transmitted through protein conformation as well as through nucleic-acid sequence. Their study connects protein folding, inheritance, infectious disease, and neurodegeneration, while presenting distinctive problems for diagnosis, animal-disease control, and the decontamination of medical materials.
Discovery and the protein-only hypothesis
Scrapie was recognized in European sheep by the eighteenth century, long before its cause was understood. Its prolonged incubation, progressive neurological signs, and transmissibility made it difficult to classify. In experiments published in 1936, Jean Cuillé and Paul-Louis Chelle demonstrated transmission to sheep using material from affected animals. Later work established that apparently healthy animals could carry infectivity for long periods before showing disease, helping distinguish an infectious process from a purely hereditary disorder.
Human diseases supplied additional evidence. Hans Gerhard Creutzfeldt and Alfons Maria Jakob described neurological cases in the early 1920s that gave Creutzfeldt–Jakob disease its name, although not all the original cases would meet modern criteria. In the 1950s, investigations of kuru among the Fore people and neighboring communities in Papua New Guinea identified a fatal neurological epidemic associated with mortuary practices involving the handling and consumption of human remains. D. Carleton Gajdusek and collaborators demonstrated transmission of kuru to chimpanzees in work reported in 1966.
The infectious agent resisted treatments that ordinarily damage nucleic acids. In 1967, the mathematician J. S. Griffith outlined mechanisms by which a protein might reproduce its biological state without carrying a conventional genome. Stanley B. Prusiner introduced the term prion, derived from “proteinaceous infectious particle,” in 1982, following biochemical studies of scrapie infectivity. The proposal challenged the prevailing expectation that every infectious agent required nucleic acid to encode its replication.
Several independent findings strengthened the protein-only hypothesis. The disease-associated protein proved to be an altered form of a normal host protein, rather than a foreign protein encoded by an unidentified pathogen. In 1989, a disease-linked variant in the human prion protein gene connected an inherited neurological syndrome to the same molecular system. In 1993, experiments showed that mice lacking functional prion protein resisted scrapie infection. Later, cell-free conversion and recombinant-protein experiments demonstrated that infectious material could be generated under defined conditions, although efficiency and cofactor requirements varied between systems.
Prusiner received the 1997 Nobel Prize in Physiology or Medicine for the discovery of prions. The protein-only hypothesis does not imply that every infectious preparation contains protein alone: host lipids, polyanions, and other molecules can assist conversion. Its central claim is that the heritable identity of the infectious agent resides primarily in a self-propagating protein structure rather than an agent-specific nucleic-acid sequence.
The normal prion protein and its disease-associated forms
The mammalian prion protein, abbreviated PrP, is encoded by the PRNP gene. In humans, PRNP lies on the short arm of chromosome 20. The initial protein contains 253 amino acids and undergoes processing that removes terminal signal sequences, adds carbohydrate groups, and attaches a glycosylphosphatidylinositol anchor. This anchor holds mature PrP on the outer surface of the cell membrane. PrP is particularly abundant in the nervous system but is also expressed in many other tissues.
The normal cellular form is conventionally written . Its structured carboxy-terminal domain contains three alpha helices and a short, two-stranded beta sheet, while much of the amino-terminal region is comparatively flexible. Repeated sequences in the amino-terminal region can bind copper and other metal ions. The protein is synthesized through the endoplasmic reticulum, processed through the secretory pathway, and repeatedly transported between the cell surface and internal compartments.
The normal physiological functions of PrP remain incompletely resolved. Experimental studies implicate it in cell signaling, responses to cellular stress, synaptic processes, and the maintenance of peripheral myelin. Mice without PrP are viable, showing that it is not universally indispensable for development or basic cellular survival, but specific abnormalities can emerge with age or under particular experimental conditions. These findings do not support a single, universally accepted account of its normal role.
Disease-associated PrP is often written , with “Sc” referring historically to scrapie. Compared with cellular PrP, it generally contains more beta-sheet structure and forms assemblies with altered solubility and resistance to degradation. Many preparations contain a core that resists digestion by proteinase K, a protein-degrading enzyme. However, protease resistance is not a defining requirement: infectious, disease-associated PrP can be protease-sensitive, and the proportion of resistant material differs among strains and diseases.
PrP molecules also differ in their glycosylation and cleavage patterns. Such differences help characterize disease-associated preparations, but they do not by themselves define infectivity. Studies using cryo-electron microscopy have resolved ordered fibrils from several mammalian prion preparations, revealing distinct ways in which the same general protein sequence can form highly organized assemblies. These structures reinforce an important distinction: a protein's amino-acid sequence constrains its behavior, but does not uniquely specify every stable conformation it can adopt.
Conformational replication and amyloid assembly
Prion propagation begins when a compatible abnormal assembly recruits normal PrP and promotes its conversion into a similar structure. The newly converted molecules become part of an assembly capable of recruiting additional substrate. The host continues to supply PrP through ordinary gene expression, while the infectious structure redirects that supply into a self-propagating state. No copying of an infectious nucleic-acid sequence is required.
Most mechanistic models describe a combination of nucleation, elongation, and fragmentation. Nucleation produces an initial assembly capable of sustained growth; this is usually much less efficient than adding protein to an existing seed. During elongation, substrate molecules join the assembly and adopt an ordered structure. Fragmentation creates additional particles or exposed ends, increasing the number of sites that can recruit further protein. Consequently, total aggregate mass and infectious particle number need not increase in parallel.
Many prion assemblies are forms of amyloid, fibrillar protein aggregates characterized by a cross-beta architecture. In this arrangement, beta strands run approximately perpendicular to the fibril axis, while beta sheets extend along it. Repeated intermolecular interactions stabilize a structure that can be both persistent and capable of templating further growth. Not every amyloid is infectious, however, and the presence of amyloid deposits alone does not establish prion disease. Infectivity depends on biological properties that include access to suitable substrate and the ability to persist and multiply in a host.
A simplified conversion scheme is:
where denotes available cellular prion protein and denotes a seed containing converted molecules. This notation describes recruitment rather than a complete chemical reaction. It omits intermediate conformations, competing degradation, cellular transport, and the effects of membranes and molecular cofactors. In particular, the microscopic structures responsible for maximal infectivity or toxicity need not be identical to the largest visible fibrils.
The process is constrained by chemical kinetics and cellular protein-quality-control systems. Some assemblies are removed before they can establish sustained replication; others grow slowly enough to remain clinically silent for years. Incubation time therefore reflects more than a single conversion rate. It also depends on dose, entry route, tissue distribution, substrate availability, host sequence, and the balance between production and clearance. This framework explains how a long symptom-free interval can precede rapidly progressive neurological disease.
Strains, host genetics, and species barriers
Prion strains are distinguishable biological variants that can maintain characteristic properties during propagation in the same host genotype. They may differ in incubation period, the distribution of brain lesions, affected cell populations, biochemical behavior, and clinical signs. In conventional pathogens, comparable differences are often encoded by genome sequence. For prions, a major source of strain information is the conformation and organization of the protein assembly.
Evidence for conformational strains includes the stable propagation of distinct biochemical patterns and the resolution of different fibril structures. Nevertheless, an infected sample need not contain one perfectly uniform population. A mixture of related conformers may be present, and changes in host environment can favor one over another. Selection among these variants can alter the observed properties of an isolate. This resembles aspects of evolution, but the inherited variable is principally a protein state rather than an agent-specific genetic sequence.
A species barrier is the reduced efficiency of prion transmission between different host species. Differences in PrP sequence can make it difficult for an incoming assembly to recruit the recipient's protein. Structural compatibility also matters, so sequence similarity alone does not reliably predict transmission. Dose, exposure route, tissue source, and strain identity further influence the outcome. Initial cross-species transmission may produce incomplete attack rates or unusually long incubation periods; subsequent passage in the new host can produce more efficient propagation.
The barrier is therefore neither absolute nor uniform. Bovine spongiform encephalopathy crossed into humans and caused variant Creutzfeldt–Jakob disease, whereas no human disease has been established as resulting from exposure to classical scrapie. Different strains originating in the same animal species may also have different host ranges. Experimental transmission, especially after direct inoculation into the brain, must be distinguished from transmission under natural exposure conditions.
Host genetic variation affects susceptibility within a species. In humans, PRNP codon 129 commonly encodes either methionine or valine. The resulting genotypes influence susceptibility, disease phenotype, and incubation in several settings. All genotyped clinical cases in the original variant Creutzfeldt–Jakob disease epidemic were methionine homozygotes; a later definite case occurred in a methionine–valine heterozygote. This does not imply that other genotypes are completely resistant.
In sheep, combinations of amino acids at PRNP codons 136, 154, and 171 strongly influence susceptibility to classical scrapie and have been used in selective-breeding programs. These relationships are strain-dependent: a genotype associated with resistance to one form of disease cannot automatically be treated as resistant to every prion.
Neuroinvasion and mechanisms of tissue injury
The route from exposure to neurological disease depends on both the prion strain and the host. After oral exposure, some prions cross the intestinal barrier and accumulate in lymphoid tissues before entering peripheral nerves. Specialized epithelial cells and immune-associated tissues in the intestine can participate in uptake. Follicular dendritic cells, which are distinct from conventional antigen-presenting dendritic cells, can support prion accumulation in lymphoid follicles. Other strains and exposure routes show less dependence on this peripheral phase.
Prions can reach the central nervous system through peripheral neural pathways, including components of the autonomic nervous system. Once established in neural tissue, propagation is influenced by anatomical connections, local PrP expression, and the susceptibility of particular cell types. The brain is therefore not damaged uniformly. Distinct patterns of involvement in the cortex, thalamus, cerebellum, and other regions help explain differences in cognition, movement, coordination, and sleep among prion diseases.
Characteristic pathology includes neuronal loss, reactive changes in glial cells, accumulation of abnormal PrP, and microscopic vacuoles in neural tissue. The vacuolated appearance gives rise to the term spongiform. Amyloid plaques occur prominently in some disorders but are absent or inconspicuous in others. Conventional inflammatory infiltrates are generally limited compared with those in many viral infections, although activation of microglia and astrocytes is an important part of disease biology.
The precise connection between prion replication and neuronal death remains unresolved. Proposed mechanisms include injury to cell membranes, disruption of protein trafficking, altered signaling, synaptic dysfunction, and activation of cellular stress pathways. Experimental findings indicate that infectivity and toxicity are not interchangeable measurements. A preparation can carry considerable infectivity without immediately causing neuronal injury, and large deposits may not be the most damaging molecular species.
The presence of host PrP is critical not only for amplification but also for important aspects of toxicity. In experimental models, reducing neuronal PrP after infection can prevent or delay neurological damage even when abnormal protein remains elsewhere. This supports a model in which disease requires ongoing interactions between replicating assemblies and susceptible cells rather than merely the passive accumulation of inert deposits.
Early dysfunction at the synapse can precede extensive neuronal loss. Because many neurological deficits arise after a long period of silent replication, the molecular events observed at clinical presentation may differ from those that initiated infection. Separating entry, replication, spread, and injury remains central to interpreting animal experiments and human tissue findings.
Human prion diseases
Human prion diseases fall into three broad etiological groups: sporadic, genetic, and acquired. Creutzfeldt–Jakob disease (CJD) is the most common. National surveillance programs generally identify approximately one to two cases of CJD per million people annually, with variation according to population age and ascertainment. Most cases are sporadic, meaning that no pathogenic PRNP variant or recognized external source of infection is identified. “Sporadic” describes the observed origin of a case, not a fully established molecular explanation.
Sporadic CJD typically occurs in later adult life and often produces rapidly progressive cognitive impairment accompanied by neurological abnormalities such as incoordination, visual disturbance, myoclonus, or pyramidal and extrapyramidal signs. The course is usually measured in months, although substantial variation occurs. Molecular subtypes, defined partly by PRNP codon 129 and the biochemical properties of abnormal PrP, show differences in presentation, duration, and brain pathology.
Genetic prion diseases are associated with pathogenic PRNP variants and generally show autosomal dominant inheritance, although penetrance varies. They include genetic CJD, Gerstmann–Sträussler–Scheinker disease, and fatal familial insomnia. Gerstmann–Sträussler–Scheinker disease often has a more prolonged course with prominent cerebellar dysfunction and PrP amyloid plaques. Fatal familial insomnia is associated with a D178N substitution in a particular codon-129 context and prominently affects sleep regulation and autonomic function, with characteristic thalamic pathology. These names describe recognizable syndromes within a wider spectrum of inherited prion phenotypes.
Acquired disease includes kuru, iatrogenic CJD, and variant CJD. Kuru declined after the associated mortuary practices ceased, but cases appearing decades later demonstrated exceptionally long incubation periods. Iatrogenic CJD has followed exposure through certain cadaver-derived pituitary hormones, dura mater grafts, and, rarely, contaminated neurosurgical instruments or corneal transplantation. These events involved particular materials and procedures; they do not indicate transmission through ordinary social contact.
Variant CJD was recognized in the United Kingdom in 1996 and linked to exposure to the bovine spongiform encephalopathy agent. Compared with typical sporadic CJD, it generally affected younger people and often began with psychiatric or sensory symptoms before overt neurological deterioration. Its pathology includes characteristic florid plaques. Transfusion-associated transmission has also been documented.
Despite their different origins, recognized human prion diseases are progressive and fatal. No treatment has been established to stop their underlying disease process. Their rarity, variable presentation, and sometimes prolonged incubation make surveillance and reliable classification especially important.
Animal prion diseases and environmental transmission
Scrapie affects sheep and goats and has been recognized for centuries. Classical scrapie can spread within flocks, with birth-associated materials and contaminated environments contributing to exposure. Clinical signs may include altered behavior, incoordination, and rubbing or scratching, although manifestations vary. Atypical scrapie, including the form originally described as Nor98, has a different epidemiological and pathological profile and is often detected in older animals. It should not be treated as simply another presentation of classical scrapie.
Bovine spongiform encephalopathy (BSE) was identified in British cattle in 1986. The classical BSE epidemic was amplified through feed containing contaminated ruminant-derived protein. Recycling infectious tissues through meat-and-bone meal created a large-scale route of exposure that would not ordinarily occur in cattle husbandry. Feed restrictions, surveillance, and removal of specified high-risk tissues from food and feed chains sharply reduced classical BSE. Rare atypical forms, designated H-type and L-type by biochemical features, have also been detected, predominantly in older cattle.
Chronic wasting disease (CWD) affects deer, elk, moose, and related cervids. It was first recognized in captive mule deer in Colorado in the late 1960s and subsequently identified as a spongiform encephalopathy. Infection has been documented in free-ranging and captive populations in North America and in additional regions. Clinical disease can involve progressive weight loss, altered behavior, incoordination, and excessive salivation, but infected animals may shed prions before obvious illness.
CWD is particularly difficult to control because transmission can occur between animals and through contaminated environments. Prions have been detected in saliva, urine, feces, and carcass-associated materials. Binding to soil minerals and other surfaces can preserve infectivity under some conditions, although persistence and bioavailability depend on the material and environment. Ordinary decomposition therefore does not necessarily eliminate an infected carcass as a source of exposure. No confirmed human case has been attributed to CWD; experimental findings concerning host barriers do not establish the outcome of natural human exposure.
Other animal disorders include transmissible mink encephalopathy, feline spongiform encephalopathy, and prion diseases reported in captive exotic ungulates. Several of these incidents were associated with contaminated feed or the BSE epidemic, illustrating how agricultural and zoological practices can create new transmission opportunities.
Animal prion surveillance combines clinical investigation, testing of selected tissues, and population monitoring. Interpretation requires attention to strain, host genotype, and sampling strategy: a negative result in one tissue or at an early stage does not necessarily establish that an animal was uninfected.
Diagnosis and experimental detection
Prion diagnosis draws on clinical features, imaging, laboratory tests, genetics, and, where available, neuropathology. In suspected sporadic CJD, magnetic resonance imaging can show characteristic abnormalities on diffusion-weighted sequences, particularly in the cerebral cortex and basal ganglia. Electroencephalography may reveal periodic sharp-wave complexes in some cases. Neither finding occurs in every patient, and other neurological conditions can produce partially overlapping patterns.
Cerebrospinal fluid tests historically included proteins such as 14-3-3 and total tau. These indicate neuronal injury rather than prions themselves, so their significance depends heavily on the clinical setting. A positive injury marker is not equivalent to demonstration of a transmissible agent. PRNP sequence analysis can establish a genetic cause when a pathogenic variant is identified, but genetic findings require interpretation because variants differ in their clinical significance and penetrance.
A major advance has been real-time quaking-induced conversion, usually abbreviated RT-QuIC. The assay exposes recombinant PrP substrate to a sample that may contain prion seeds. Repeated shaking promotes seeded assembly, while a fluorescent dye detects the formation of amyloid-like aggregates. Applied to cerebrospinal fluid and, in specialized settings, other samples, RT-QuIC provides highly specific evidence of prion seeding activity. Sensitivity varies with disease subtype, specimen, and assay conditions, so a negative result does not exclude every prion disorder.
Another method, protein misfolding cyclic amplification (PMCA), alternates incubation with mechanical disruption, often by sonication. This allows growing assemblies to generate additional seeds and can amplify very small initial quantities. PMCA commonly uses biological substrates that supply PrP and associated molecules. In contrast, RT-QuIC generally uses recombinant substrate and is designed primarily to detect seeding through a measurable fluorescence signal. Assay positivity, seed concentration, and infectious dose remain related but nonidentical quantities.
Definitive classification often depends on examination of brain tissue, including histology, immunohistochemistry, and biochemical analysis. Immunoblotting after controlled protease digestion can reveal characteristic PrP fragment and glycosylation patterns. Structural analysis and transmission studies provide additional information in research, but they are not interchangeable with routine clinical tests.
Animal bioassays historically provided the strongest operational demonstration of infectivity: disease was transmitted to a susceptible recipient and characterized after incubation. Such experiments are slow, costly, and dependent on the recipient model. Modern seeding assays greatly accelerate detection, but their interpretation still depends on validated relationships between the measured signal, the sample type, and the biological question.
Resistance, decontamination, and public-health control
Prions are unusually resistant to several processes that effectively inactivate conventional pathogens. Their stability reflects the properties of aggregated protein, association with biological materials, and binding to surfaces. Treatments that principally damage nucleic acids may have limited effects because the infectious state does not depend on an agent-specific nucleic-acid genome. Standard disinfectants and routine sterilization conditions therefore cannot automatically be assumed to eliminate prion infectivity.
Resistance is relative rather than absolute. Its measurement depends on strain, starting concentration, tissue composition, exposure conditions, and the sensitivity of the infectivity assay. Material dried onto a surface can behave differently from material suspended in liquid. Prions also adhere strongly to stainless steel, an important consideration for surgical instruments. A treatment that greatly reduces infectivity may still leave a detectable residual amount when the starting burden is high.
Health authorities have developed specialized procedures for materials exposed to suspected prion contamination. These can involve combinations of chemical treatment and high-temperature processing, or destruction of selected materials. The procedures are specific to the instrument, tissue exposure, and clinical context; they are distinct from ordinary cleaning protocols. Laboratory work with prions likewise uses risk assessments that account for inoculation hazards, contaminated sharps, sample concentration, and the long interval before an accidental exposure could become clinically apparent.
Population-level control has depended largely on interrupting particular transmission routes. During the BSE crisis, controls on animal feed and the exclusion of specified risk materials reduced the recycling of infectivity. Changes in the sourcing and manufacture of human biological products ended major historical routes associated with cadaver-derived pituitary hormones. Blood services have also used donor-selection and component-processing policies in response to variant CJD, with policies changing as evidence and epidemiological circumstances evolved.
Prion diseases are not spread by ordinary proximity to an affected person. Their transmission requires particular biological exposures, and the relevant tissue distribution differs among disorders. Variant CJD, for example, has more extensive involvement of lymphoreticular tissues than typical sporadic CJD, a distinction with implications for surveillance and blood safety.
Long incubation periods create a distinctive problem for public health: exposure and recognized disease may be separated by decades. Reliable investigation therefore depends on linked clinical, laboratory, veterinary, and exposure records. The absence of immediate cases after a suspected exposure is not a direct measurement of whether transmission occurred.
Fungal prions, prion-like proteins, and unresolved questions
Prions are not confined to mammalian disease. In the yeast Saccharomyces cerevisiae, certain proteins can adopt self-propagating states inherited through the cytoplasm. The best-known examples include the state of Sup35 and the state of Ure2. Sup35 normally participates in translation termination; when much of it enters the prion state, termination becomes less efficient, changing the expression of some genetic information. Ure2 prion formation alters its role in nitrogen-related regulation.
Reed Wickner's 1994 proposal that these yeast elements were prions connected unusual non-Mendelian inheritance to self-perpetuating protein conformations. Unlike mammalian transmissible spongiform encephalopathies, fungal prion states are not necessarily lethal. Their effects can be harmful, neutral, or advantageous under particular conditions. Some can also be lost, producing descendants without the prion state even though their underlying DNA sequence remains unchanged. They therefore provide a well-defined example of protein-based epigenetic inheritance.
Cellular chaperones are central to fungal prion maintenance. Hsp104, together with other protein-quality-control factors, can fragment assemblies and create transmissible seeds. If fragmentation is insufficient, aggregates may become too large or too few to pass reliably to daughter cells. Excessive disassembly can also eliminate some prion states. Thus, inheritance depends not only on the stability of an assembly but on a cellular system that generates and distributes propagating particles.
The term prion-like is also applied to proteins involved in other neurodegenerative disorders, including amyloid-beta and tau in Alzheimer's disease and alpha-synuclein in Parkinson's disease. These proteins can show seeded aggregation and spread in experimental systems. Nevertheless, molecular seeding, movement between cells, and natural infectious transmission are different claims. Evidence of a prion-like mechanism does not establish that a disorder is contagious through everyday contact or shares the epidemiology of classical prion disease.
Self-templating protein states have additionally been investigated in normal biological functions, including persistent changes in neuronal activity. The classification of such systems depends on whether a state truly propagates, survives molecular turnover, and is transmitted between cells or cellular generations. A protein region with an aggregation-prone sequence is not, by that fact alone, a demonstrated prion.
Major unresolved questions in mammalian systems include the origin of sporadic disease, the identity of the most neurotoxic assemblies, the structural basis of strain selection, and the determinants of species barriers. Experimental treatment strategies include reducing PrP production, stabilizing nonpathogenic states, and interfering with propagation or cellular injury. Each targets a different stage of the process, making the timing of intervention and the relationship between seeding activity and tissue damage central problems in therapeutic research.